Get the Stockscreener App
16.74
2.62%
-0.45
After Hours:
16.74
Cullinan Therapeutics Inc stock is traded at $16.74, with a volume of 333.32K.
It is down -2.62% in the last 24 hours and down -14.59% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
See More
Previous Close:
$17.19
Open:
$17.05
24h Volume:
333.32K
Relative Volume:
0.49
Market Cap:
$969.37M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-4.9674
EPS:
-3.37
Net Cash Flow:
$-134.48M
1W Performance:
+0.66%
1M Performance:
-14.59%
6M Performance:
-1.76%
1Y Performance:
+84.97%
1-Day Range:
$16.54
$17.54
1-Week Range:
$16.20
$18.40
52-Week Range:
$7.64
$30.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Perceptive Advisors LLC Takes Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Ensign Peak Advisors Inc Acquires Shares of 148,773 Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Lynx1 Capital Management LP Buys New Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
There is no doubt that Cullinan Therapeutics Inc (CGEM) ticks all the boxes. - SETE News
Renaissance Technologies LLC Has $7.36 Million Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market - Benzinga
Cullinan Therapeutics Inc (CGEM)’s stock price in review: A technical analysis - US Post News
Quarterly Metrics: Quick and Current Ratios for Cullinan Therapeutics Inc (CGEM) - The Dwinnex
CGEM’s Debt-to-Equity Ratio at 0.00: What It Means for Cullinan Therapeutics Inc’s Future - The InvestChronicle
Paradigm Capital Management Inc. NY Has $39.46 Million Stock Holdings in Concentrix Co. (NASDAQ:CNXC) - MarketBeat
Rhumbline Advisers Raises Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Highlights of Current Entertainment News - Devdiscourse
Four Tri-City actors cast in Willy Wonka's wacky chocolate world - The Tri-City News
Transgender Singer Xavian Wu's Journey, China's Micro Dramas, and Meryl Streep's UN Solidarity - Devdiscourse
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 9.2% - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 9.2% - Defense World
Cullinan Therapeutics Files Investigational New Drug Application with FDA for CLN-978 for Treatment of Systemic Lupus Erythematosus - Lupus Foundation of America
FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks - Nasdaq
BTIG maintains Buy rating on Cullinan Oncology stock By Investing.com - Investing.com Australia
Cullinan Oncology maintains Buy rating from H.C. Wainwright with steady price target - Investing.com Australia
Cullinan Therapeutics (NASDAQ:CGEM) Given Outperform Rating at Wedbush - Defense World
BTIG maintains Buy rating on Cullinan Oncology stock By Investing.com - Investing.com Canada
BTIG maintains Buy rating on Cullinan Oncology stock - Investing.com
Cullinan Oncology maintains Buy rating from H.C. Wainwright with steady price target - Investing.com India
Wedbush Reaffirms "Outperform" Rating for Cullinan Therapeutics (NASDAQ:CGEM) - MarketBeat
Analysts review Cullinan Therapeutics Inc’s rating - Knox Daily
Objective long/short (CGEM) Report - Stock Traders Daily
E Fund Management Co. Ltd. Takes $1.31 Million Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Australian HREC grants clearance for Cullinan Therapeutics’ SLE treatment trial - Clinical Trials Arena
Australian HREC grants clearance for Cullinan Therapeutics’ SLE treatment trial - Yahoo Finance
Cullinan Therapeutics commences Phase 1 trial for lupus treatment - Investing.com
Cullinan Therapeutics commences Phase 1 trial for lupus treatment By Investing.com - Investing.com Canada
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 5.5% - MarketBeat
Cullinan Therapeutics commences Phase 1 trial for lupus treatment By Investing.com - Investing.com UK
Cullinan Therapeutics Receives Approval to Initiate its - GlobeNewswire
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus - StockTitan
Cullinan Oncology holds stock target with Buy rating post-ESMO By Investing.com - Investing.com Canada
Bank of New York Mellon Corp Has $2.41 Million Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up to $17.95 - MarketBeat
Cullinan Oncology holds stock target with Buy rating post-ESMO - Investing.com
Cullinan Oncology holds stock target with Buy rating post-ESMO - Investing.com India
Analyzing Ratios: Cullinan Therapeutics Inc (CGEM)’s Financial Story Unveiled - The Dwinnex
Cullinan Oncology's stock gets buy rating after trial data By Investing.com - Investing.com Australia
Perhaps timely catching Cullinan Therapeutics Inc (CGEM) would be a good idea - SETE News
Cullinan Therapeutics files IND application for CLN-978 to treat SLE - BioWorld Online
Cullinan Therapeutics' (CGEM) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Cullinan seeks FDA nod for lupus treatment - Investing.com
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus - StockTitan
Cullinan Therapeutics Announces Submission of - GlobeNewswire
Cullinan Therapeutics, Inc. Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus - Marketscreener.com
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Price Target at $32.00 - MarketBeat
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):